Information About Vaxzevria

Disclaimer: The information on this page is intended for Healthcare Professionals only.

A Marketing Authorisation has been granted in the EU for the product Vaxzevria for active immunisation of individuals aged 18 years and older for the prevention of coronavirus disease 2019 (COVID-19).

You can find more information here (https://www.ema.europa.eu/en).

During the pandemic, Vaxzevria may also be distributed in packaging with the name COVID‑19 Vaccine AstraZeneca.

Patient Information Leaflet (PIL) [English]
Patient Information Leaflet (PIL) [Malti]
Summary of Product Characteristics (SPC) [English]
Summary of Product Characteristics (SPC) [Malti]
Blue Box
Traceability and Vaccination Reminder Card

Report an Adverse Event via the Medicines Authority ADR website

If you are concerned about an adverse event, it can be reported via the Medicines Authority ADR website:  http://medicinesauthority.gov.mt/adrportal

Report an Adverse Event via the Medicines Authority ADR website

This link will take you to another website. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

 

AstraZeneca Vaccine Reporting

Submit a Product Quality Complaint

© AstraZeneca. All rights reserved.

This website is intended for people seeking information on Vaxzevria

exit ramp cf

azcovid-cf-text

You are now leaving azcovid-19.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s Vaccine site or ‘continue’ to proceed.

az-cancle-cta
Cancel
az-submit-cta
Continue